By Sheeba M. | June 08, 2026
Aurora Cannabis ACB: Revenue Recovery Accelerating in Q2
Aurora Cannabis (TSX: ACB, OTC: ACBFF) is demonstrating margin recovery that institutional investors have been waiting for. Q1 2026 preliminary data shows the company’s adult-use segment gaining traction with 28% quarter-over-quarter growth, driven by market share gains in Ontario and British Columbia.
The company’s focus on high-margin extraction products—particularly vape cartridges and edibles—is paying dividends. ACB’s gross margin improved 340 basis points sequentially, reflecting improved production efficiency and product mix optimization. This is critical because profitability, not just revenue, is what drives institutional buying.
Key catalyst: Aurora’s international expansion, particularly in Germany, is ramping faster than expected. European operations contributed $4.2M in Q1, up from $2.8M in Q4. If this trajectory holds, international revenue could represent 18-20% of total revenue by year-end—a material revenue diversification away from domestic market saturation.
The risk remains execution. Aurora has promised margin improvements before. But the cost restructuring ($75M in annualized savings achieved) appears structural this time, not temporary. Watch June 15 earnings for confirmation.
Key Tickers: $ACB $CURLF $HEXO $TRSSF $CCHWF
Sources
Track cannabis stocks with the Weedstock Real-Time Tracker